Skip to main content
PMC home page
Public Health Reports logoLink to Public Health Reports
. 2002;117(Suppl 1):S60–S66.

Predictors of hospitalization for HIV-positive women and men drug users, 1996-2000.

Ellie E Schoenbaum 1, Yungtai Lo 1, Michelle Floris-Moore 1
PMCID: PMC1913710  PMID: 12435828

Abstract

OBJECTIVE: This study sought to determine whether health outcomes differed by gender in a cohort of African American, Hispanic American, and white drug users. METHODS: The authors studied hospitalization rates and discharge diagnoses in the HERO Study, an ongoing prospective study of drug users that included HIV-positive and HIV-negative opiate users. The data are from 1996-2000, when highly active antiretroviral therapy (HAART) was available. RESULTS: Women had higher rates of hospitalization than men independent of HIV status, and there was no association between ethnicity and hospitalization. Being a woman was an independent risk factor for HIV and non-HIV-related hospitalization. CONCLUSION: Health disparities between men and women extend to HIV.

Full text

PDF
S63

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnsten J. H., Demas P. A., Farzadegan H., Grant R. W., Gourevitch M. N., Chang C. J., Buono D., Eckholdt H., Howard A. A., Schoenbaum E. E. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis. 2001 Sep 5;33(8):1417–1423. doi: 10.1086/323201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bassetti S., Battegay M., Furrer H., Rickenbach M., Flepp M., Kaiser L., Telenti A., Vernazza P. L., Bernasconi E., Sudre P. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 1999 Jun 1;21(2):114–119. [PubMed] [Google Scholar]
  3. Celentano D. D., Galai N., Sethi A. K., Shah N. G., Strathdee S. A., Vlahov D., Gallant J. E. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS. 2001 Sep 7;15(13):1707–1715. doi: 10.1097/00002030-200109070-00015. [DOI] [PubMed] [Google Scholar]
  4. Celentano D. D., Vlahov D., Cohn S., Shadle V. M., Obasanjo O., Moore R. D. Self-reported antiretroviral therapy in injection drug users. JAMA. 1998 Aug 12;280(6):544–546. doi: 10.1001/jama.280.6.544. [DOI] [PubMed] [Google Scholar]
  5. Detels R., Muñoz A., McFarlane G., Kingsley L. A., Margolick J. B., Giorgi J., Schrager L. K., Phair J. P. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA. 1998 Nov 4;280(17):1497–1503. doi: 10.1001/jama.280.17.1497. [DOI] [PubMed] [Google Scholar]
  6. Gebo K. A., Diener-West M., Moore R. D. Hospitalization rates in an urban cohort after the introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001 Jun 1;27(2):143–152. doi: 10.1097/00126334-200106010-00009. [DOI] [PubMed] [Google Scholar]
  7. Lucas G. M., Chaisson R. E., Moore R. D. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999 Jul 20;131(2):81–87. doi: 10.7326/0003-4819-131-2-199907200-00002. [DOI] [PubMed] [Google Scholar]
  8. Mocroft A., Madge S., Johnson A. M., Lazzarin A., Clumeck N., Goebel F. D., Viard J. P., Gatell J., Blaxhult A., Lundgren J. D. A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. J Acquir Immune Defic Syndr. 1999 Dec 1;22(4):369–378. doi: 10.1097/00126334-199912010-00008. [DOI] [PubMed] [Google Scholar]
  9. Mouton Y., Alfandari S., Valette M., Cartier F., Dellamonica P., Humbert G., Lang J. M., Massip P., Mechali D., Leclercq P. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Fédération National des Centres de Lutte contre le SIDA. AIDS. 1997 Oct;11(12):F101–F105. doi: 10.1097/00002030-199712000-00003. [DOI] [PubMed] [Google Scholar]
  10. Palepu A., Tyndall M. W., Leon H., Muller J., O'Shaughnessy M. V., Schechter M. T., Anis A. H. Hospital utilization and costs in a cohort of injection drug users. CMAJ. 2001 Aug 21;165(4):415–420. [PMC free article] [PubMed] [Google Scholar]
  11. Schaubel D. E., Stewart D. E., Morrison H. I., Zimmerman D. L., Cameron J. I., Jeffery J. J., Fenton S. S. Sex inequality in kidney transplantation rates. Arch Intern Med. 2000 Aug 14;160(15):2349–2354. doi: 10.1001/archinte.160.15.2349. [DOI] [PubMed] [Google Scholar]
  12. Selwyn P. A., Alcabes P., Hartel D., Buono D., Schoenbaum E. E., Klein R. S., Davenny K., Friedland G. H. Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. N Engl J Med. 1992 Dec 10;327(24):1697–1703. doi: 10.1056/NEJM199212103272401. [DOI] [PubMed] [Google Scholar]
  13. Shapiro M. F., Morton S. C., McCaffrey D. F., Senterfitt J. W., Fleishman J. A., Perlman J. F., Athey L. A., Keesey J. W., Goldman D. P., Berry S. H. Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA. 1999 Jun 23;281(24):2305–2315. doi: 10.1001/jama.281.24.2305. [DOI] [PubMed] [Google Scholar]
  14. Tashima K. T., Hogan J. W., Gardner L. I., Korkontzelou C., Schoenbaum E. E., Schuman P., Rompalo A., Carpenter C. C. A longitudinal analysis of hospitalization and emergency department use among human immunodeficiency virus-infected women reporting protease inhibitor use. Clin Infect Dis. 2001 Nov 7;33(12):2055–2060. doi: 10.1086/323978. [DOI] [PubMed] [Google Scholar]
  15. Turner B. J., Zhang D., Laine C., Pomerantz R. J., Cosler L., Hauck W. W. Association of provider and patient characteristics with HIV-infected women's antiretroviral therapy regimen. J Acquir Immune Defic Syndr. 2001 May 1;27(1):20–29. doi: 10.1097/00126334-200105010-00004. [DOI] [PubMed] [Google Scholar]
  16. Vakili B. A., Kaplan R. C., Brown D. L. Sex-based differences in early mortality of patients undergoing primary angioplasty for first acute myocardial infarction. Circulation. 2001 Dec 18;104(25):3034–3038. doi: 10.1161/hc5001.101060. [DOI] [PubMed] [Google Scholar]
  17. Waidmann T. A., Rajan S. Race and ethnic disparities in health care access and utilization: an examination of state variation. Med Care Res Rev. 2000;57 (Suppl 1):55–84. doi: 10.1177/1077558700057001S04. [DOI] [PubMed] [Google Scholar]
  18. Weber A. E., Yip B., O'Shaughnessy M. V., Montaner J. S., Hogg R. S. Determinants of hospital admission among HIV-positive people in British Columbia. CMAJ. 2000 Mar 21;162(6):783–786. [PMC free article] [PubMed] [Google Scholar]

Articles from Public Health Reports are provided here courtesy of SAGE Publications

RESOURCES